ACS Chemical Biology · 2019 · 23 citations · 23 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular VirologyProtein-protein InteractionsAntiretroviral TherapyLigand BindingPeptide ChemistryPeptide Drug DiscoveryPeptidomimetic DesignProtein StructureAntiviral PeptidesCyclic Peptide DesignCyclic Peptide LibrariesCyclic PeptidesPeptide Medicinal ChemistryPeptide Structure - Activity RelationshipsPeptidomimetic ModulatorsTsg101 Complex
The budding of HIV from infected cells is driven by the protein–protein interaction between the p6 domain of the HIV Gag protein and the UEV domain of the human TSG101 protein. We report the development of a cyclic peptide inhibitor of the p6/UEV interaction, from a non cell-permeable parent that was identified in a SICLOPPS screen. Amino acids critical for the activity of the parent cyclic peptide were uncovered using alanine-scanning, and a series of non-natural analogues synthesized and assessed. The most potent molecule disrupts the p6/UEV interaction with an IC50 of 6.17 ± 0.24 μM by binding to UEV with a Kd of 11.9 ± 2.8 μM. This compound is cell permeable and active in a cellular virus-like particle budding assay with an IC50 of ∼2 μM. This work further demonstrates the relative simplicity with which the potency and activity of cyclic peptides identified from SICLOPPS libraries can be optimized.
23
Tsg101 and the Vacuolar Protein Sorting Pathway Are Essential for HIV-1 Budding
Jennifer Garrus, Uta K. von Schwedler, Owen Pornillos et al. · Cell · 2001 · 1.4K citations · Full text
Lynn VerPlank, Fadila Bouamr, Tracy J. LaGrassa et al. · Proceedings of the National Academy of Sciences · 2001 · 585 citations · Full text